>Mercado europeo de diagnóstico molecular, por productos (reactivos y kits, instrumentos y servicios y software), tecnología (espectrometría de masas (MS), electroforesis capilar, secuenciación de próxima generación (NGS), chips y microarrays, métodos basados en la reacción en cadena de la polimerasa (PCR), citogenética, hibridación in situ (ISH o FISH), imágenes moleculares y otros), aplicación (oncología, farmacogenómica, microbiología, pruebas prenatales, tipificación de tejidos, detección de sangre, enfermedades cardiovasculares, enfermedades neurológicas, enfermedades infecciosas y otras), usuario final (hospital, laboratorios clínicos y académicos), país (Alemania, Francia, España, Turquía, Reino Unido, Países Bajos, Rusia, Suiza, Bélgica, Italia y resto de Europa), tendencias de la industria y pronóstico hasta 2028.
Análisis y perspectivas del mercado: mercado europeo de diagnóstico molecular
Se espera que el mercado de diagnóstico molecular gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 5,5% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 13.637,22 millones para 2028. Se espera que el aumento de la prevalencia de enfermedades infecciosas y cáncer impulse el crecimiento del mercado de diagnóstico molecular.
El diagnóstico molecular identifica o diagnostica enfermedades como enfermedades infecciosas , enfermedades genéticas, enfermedades cardiovasculares, enfermedades neurológicas y otras mediante el estudio de moléculas como ADN, ARN, proteínas en un tejido o un fluido. Diferentes tecnologías como PCR, espectrometría de masas, secuenciación de β-generación, citogenética, hibridación in situ, imágenes moleculares y otras se utilizan para diagnosticar diferentes enfermedades.
Se espera que la creciente demanda de herramientas de diagnóstico molecular para diagnosticar COVID-19 impulse el crecimiento del mercado de diagnóstico molecular. Se espera que el alto costo de la instrumentación actúe como una restricción importante para el crecimiento del mercado de diagnóstico molecular. Se espera que el aumento de la población geriátrica actúe como una oportunidad para el crecimiento del mercado de diagnóstico molecular. Se espera que la alta competencia entre los actores del mercado actúe como un desafío para el crecimiento del mercado de diagnóstico molecular.
El informe de mercado de diagnóstico molecular proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de diagnóstico molecular, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de diagnóstico molecular
The molecular diagnostics market is segmented based on the products, technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of products, the molecular diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instruments segment is expected to dominate the molecular diagnostics market due to the rise in demand for advanced technology to diagnose diseases such as infectious diseases, cancer and others.
- On the basis of technology, the molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.
- On the basis of application, the molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases and others. In 2021, the infectious diseases segment is expected to dominate the molecular diagnostics market due to the rise in infectious diseases such as flu, COVID-19, AIDS and others and the increased demand for highly efficient molecular diagnostics technology.
- On the basis of end user, the molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.
Europe Molecular Diagnostics Market Country Level Analysis
Europe molecular diagnostics market is analyzed and market size information is provided by the country, products, technology, application and end user as referenced above.
The countries covered in the Europe molecular diagnostics market report are the Germany, France, Spain, Turkey, U.K., Netherlands, Russia, Switzerland, Belgium, Italy and rest of Europe.
The products segment in Germany region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for diagnosis instrument to diagnose COVID-19 patients and other cardiovascular diseases, infectious diseases and others. The products segment in Belgium is dominating the Europe molecular diagnostics market owing to increased healthcare expenditure. The U.K. is leading the growth of the Europe molecular diagnostics market for risk segment due to increasing demand for point-of-care testing and precision medicine.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to enhance the Awareness for Molecular Diagnostics is Boosting the Molecular Diagnostics Market Growth
The molecular diagnostics market also provides you with detailed market analysis for every country growth in molecular diagnostics market. Additionally, it provides the detail information regarding the molecular diagnostics market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.
Competitive Landscape and Molecular Diagnostics Market Share Analysis
The molecular diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe molecular diagnostics market.
The major companies which are dealing in the Europe molecular diagnostics market report are Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, F Hoffmann-La Roche Ltd and GenMark Diagnostics, Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Numerosos contratos, acuerdos y lanzamientos son también iniciados por empresas de todo el mundo que están acelerando también el mercado del diagnóstico molecular.
Por ejemplo,
- En junio de 2021, Thermo Fisher Scientific Inc. lanzó un nuevo producto llamado Attune CytPix, un citómetro de flujo fluorescente que ofrece imágenes mejoradas y enfoque acústico con una cámara de alta velocidad.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la presencia de la empresa en el mercado de diagnóstico molecular, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE MOLECULAR DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRODUCT AND BRAND ANALYSIS: EUROPE MOLECULAR DIAGNOSTICS MARKET
4.2 ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN EUROPE MOLECULAR DIAGNOSTICS MARKET
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING DEMAND FOR MOLECULAR DIAGNOSTIC TOOLS TO DIAGNOSE COVID-19
5.1.2 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER
5.1.3 RISING FUNDING FOR MOLECULAR DIAGNOSIS PRODUCTS
5.1.4 RISING DEMAND FOR POINT-OF-CARE (POC) TESTING
5.1.5 DEVELOPMENT OF COMPANION DIAGNOSTIC ASSAY AND PERSONALIZED MEDICINES
5.2 RESTRAINTS
5.2.1 HIGH COST OF INSTRUMENTATIONS
5.2.2 STRINGENT LEGAL AND REGULATORY STANDARDS ARE EXPECTED TO HAMPER THE MARKET GROWTH
5.2.3 DELAY IN APPROVAL OF EXPERIMENTAL TEST FOR MOLECULAR DIAGNOSIS
5.3 OPPORTUNITIES
5.3.1 RISING GERIATRIC POPULATION
5.3.2 INCREASING ADOPTION OF ANALYSER SOFTWARE FOR MOLECULAR DIAGNOSIS
5.3.3 RISING AWARENESS REGARDING RAPID TECHNOLOGICAL ADVANCEMENTS
5.3.4 RISING HEALTHCARE EXPENDITURE IN DEVELOPING REGION
1.4 CHALLENGES
5.3.5 HIGH COMPETITION AMONG MARKET PLAYERS
5.3.6 DISTURBED SUPPLY CHAIN DUE TO COVID-19
6 IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.1 ANALYSIS ON IMPACT OF COVID-19 ON THE EUROPE MOLECULAR DIAGNOSTICS MARKET
6.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVES FOR GROWTH OF THE MOLECULAR DIAGNOSTICS MARKET
6.3 IMPACT ON DEMAND
6.4 IMPACT ON SUPPLY CHAIN
6.5 IMPACT ON PRICE
6.6 STRATEGIC INITIATIVES BY MANUFACTURERS
6.7 THE RISING COVID-19 CASES IS LEADING THE MOLECULAR DIAGNOSTICS MARKET
6.8 CONCLUSION
7 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 FULLY AUTOMATED INSTRUMENTS
7.2.2 SEMI-AUTOMATED INSTRUMENTS
7.3 REAGENTS AND KITS
7.4 SERVICES AND SOFTWARES
8 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
8.2.1 REAL-TIME PCR
8.2.2 DIGITAL PCR
8.2.3 REVERSE TRANSCRIPTASE PCR
8.2.4 QUANTITATIVE FLUORESCENT PCR
8.2.5 DIRECT LINEAR ANALYSIS
8.2.6 COLD PCR
8.3 NEXT GENERATION SEQUENCING (NGS)
8.4 CYTOGENETICS
8.5 CAPILLARY ELECTROPHORESIS
8.6 IN SITU HYBRIDIZATION (ISH OR FISH)
8.7 MOLECULAR IMAGING
8.7.1 OPTICAL IMAGING
8.7.2 FDG-PET
8.8 MASS SPECTROMETRY (MS)
8.9 CHIPS AND MICROARRAY
8.1 OTHERS
9 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 INFECTIOUS DISEASES
9.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.2.2 NEXT GENERATION SEQUENCING (NGS)
9.2.3 CYTOGENETICS
9.2.4 CAPILLARY ELECTROPHORESIS
9.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.2.6 MOLECULAR IMAGING
9.2.7 MASS SPECTROMETRY (MS)
9.2.8 CHIPS AND MICROARRAY
9.2.9 OTHERS
9.3 MICROBIOLOGY
9.3.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.3.2 NEXT GENERATION SEQUENCING (NGS)
9.3.3 CYTOGENETICS
9.3.4 CAPILLARY ELECTROPHORESIS
9.3.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.3.6 MOLECULAR IMAGING
9.3.7 MASS SPECTROMETRY (MS)
9.3.8 CHIPS AND MICROARRAY
9.3.9 OTHERS
9.4 BLOOD SCREENING
9.4.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.4.2 NEXT GENERATION SEQUENCING (NGS)
9.4.3 CYTOGENETICS
9.4.4 CAPILLARY ELECTROPHORESIS
9.4.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.4.6 MOLECULAR IMAGING
9.4.7 MASS SPECTROMETRY (MS)
9.4.8 CHIPS AND MICROARRAY
9.4.9 OTHERS
9.5 ONCOLOGY
9.5.1 ONCOLOGY, BY CANCER TYPE
9.5.1.1 BREAST CANCER
9.5.1.2 COLORECTAL CANCER
9.5.1.3 LUNG CANCER
9.5.1.4 PROSTATE CANCER
9.5.1.5 OTHERS
9.5.2 ONCOLOGY, BY TECHNOLOGY
9.5.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.5.2.2 NEXT GENERATION SEQUENCING (NGS)
9.5.2.3 CYTOGENETICS
9.5.2.4 CAPILLARY ELECTROPHORESIS
9.5.2.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.5.2.6 MOLECULAR IMAGING
9.5.2.7 MASS SPECTROMETRY (MS)
9.5.2.8 CHIPS AND MICROARRAY
9.5.2.9 OTHERS
9.6 TISSUE TYPING
9.6.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.6.2 NEXT GENERATION SEQUENCING (NGS)
9.6.3 CYTOGENETICS
9.6.4 CAPILLARY ELECTROPHORESIS
9.6.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.6.6 MOLECULAR IMAGING
9.6.7 MASS SPECTROMETRY (MS)
9.6.8 CHIPS AND MICROARRAY
9.6.9 OTHERS
9.7 PHARMACOGENOMICS
9.7.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.7.2 NEXT GENERATION SEQUENCING (NGS)
9.7.3 CYTOGENETICS
9.7.4 CAPILLARY ELECTROPHORESIS
9.7.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.7.6 MOLECULAR IMAGING
9.7.7 MASS SPECTROMETRY (MS)
9.7.8 CHIPS AND MICROARRAY
9.7.9 OTHERS
9.8 PRENATAL TESTS
9.8.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.8.2 NEXT GENERATION SEQUENCING (NGS)
9.8.3 CYTOGENETICS
9.8.4 CAPILLARY ELECTROPHORESIS
9.8.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.8.6 MOLECULAR IMAGING
9.8.7 MASS SPECTROMETRY (MS)
9.8.8 CHIPS AND MICROARRAY
9.8.9 OTHERS
9.9 NEUROLOGICAL DISEASES
9.9.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.9.2 NEXT GENERATION SEQUENCING (NGS)
9.9.3 CYTOGENETICS
9.9.4 CAPILLARY ELECTROPHORESIS
9.9.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.9.6 MOLECULAR IMAGING
9.9.7 MASS SPECTROMETRY (MS)
9.9.8 CHIPS AND MICROARRAY
9.9.9 OTHERS
9.1 CARDIOVASCULAR DISEASES
9.10.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.10.2 NEXT GENERATION SEQUENCING (NGS)
9.10.3 CYTOGENETICS
9.10.4 CAPILLARY ELECTROPHORESIS
9.10.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.10.6 MOLECULAR IMAGING
9.10.7 MASS SPECTROMETRY (MS)
9.10.8 CHIPS AND MICROARRAY
9.10.9 OTHERS
9.11 OTHERS
9.11.1 POLYMERASE CHAIN REACTION (PCR)-BASED METHODS
9.11.2 NEXT GENERATION SEQUENCING (NGS)
9.11.3 CYTOGENETICS
9.11.4 CAPILLARY ELECTROPHORESIS
9.11.5 IN SITU HYBRIDIZATION (ISH OR FISH)
9.11.6 MOLECULAR IMAGING
9.11.7 MASS SPECTROMETRY (MS)
9.11.8 CHIPS AND MICROARRAY
9.11.9 OTHERS
10 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 HOSPITAL
10.4 ACADEMICS
11 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 ITALY
11.1.4 RUSSIA
11.1.5 U.K.
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 NETHERLANDS
11.1.11 REST OF EUROPE
12 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT
14 COMPANY PROFILES
14.1 ABBOTT LABORATORIES
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 F. HOFFMANN-LA ROCHE LTD
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ILLUMINA, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 HOLOGIC, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BIOMÉRIEUX SA
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 REVENUE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AGILENT TECHNOLOGIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 BD
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BECKMAN COULTER, INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BIO-RAD LABORATORIES, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENTS
14.1 CEPHEID
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 GENMARK DIAGNOSTICS, INC.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 IMMUCOR
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 LIFE TECHNOLOGIES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 LUMINEX CORPORATION
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 MERRIDIAN BIOSCIENCE
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 MYRIAD GENETICS, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 QIAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 QUIDEL CORPORATION
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 SIEMENS HEALTHCARE GMBH
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 THERMO FISHER SCIENTIFIC INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 2 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 EUROPE REAGENTS AND KITS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 EUROPE SERVICES AND SOFTWARES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 9 EUROPE NEXT GENERATION SEQUENCING (NGS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE CYTOGENETICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE CAPILLARY ELECTROPHORESIS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE INS SITU HYBRIDIZATION (ISH OR FISH) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 15 EUROPE MASS SPECTROMETRY (MS) IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE CHIPS AND MICROARRAY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 21 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 23 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 25 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 EUROPE ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 27 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 EUROPE CLINICAL LABORATORIES IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 EUROPE HOSPITAL IN MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 EUROPE ACADEMICS IN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 44 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 45 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 EUROPE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 47 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 48 EUROPE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 49 EUROPE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 50 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 51 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 52 EUROPE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 EUROPE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 55 EUROPE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 EUROPE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 EUROPE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 EUROPE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 EUROPE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 EUROPE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 EUROPE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 GERMANY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 66 GERMANY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 67 GERMANY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 68 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 70 GERMANY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 71 GERMANY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 GERMANY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 GERMANY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 74 GERMANY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 GERMANY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 GERMANY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 GERMANY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 78 GERMANY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 GERMANY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 80 GERMANY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 82 FRANCE INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 83 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 84 FRANCE POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 85 FRANCE MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 87 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 88 FRANCE ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 89 FRANCE PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 FRANCE MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 FRANCE PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 FRANCE TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 FRANCE BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 94 FRANCE CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 95 FRANCE NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 96 FRANCE INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 FRANCE OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 98 FRANCE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 ITALY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 100 ITALY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 101 ITALY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 ITALY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 ITALY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 ITALY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 106 ITALY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 107 ITALY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 108 ITALY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 ITALY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 ITALY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 ITALY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 ITALY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 ITALY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 ITALY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 115 ITALY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 116 ITALY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 117 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 118 RUSSIA INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 119 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 RUSSIA POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 RUSSIA MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 124 RUSSIA ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 125 RUSSIA PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 126 RUSSIA MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 127 RUSSIA PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 128 RUSSIA TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 129 RUSSIA BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 130 RUSSIA CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 131 RUSSIA NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 RUSSIA INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 RUSSIA OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 134 RUSSIA MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 135 U.K. MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 U.K. INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 137 U.K. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 138 U.K. POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 139 U.K. MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 140 U.K. MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 141 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 142 U.K. ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 U.K. PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 144 U.K. MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 145 U.K. PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 U.K. TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 U.K. BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 U.K. CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 U.K. NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 U.K. INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 U.K. OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 U.K. MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 154 SPAIN INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 156 SPAIN POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 157 SPAIN MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 158 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 159 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 160 SPAIN ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 161 SPAIN PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 SPAIN MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 SPAIN PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 164 SPAIN TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 165 SPAIN BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 166 SPAIN CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 167 SPAIN NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 168 SPAIN INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 169 SPAIN OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 170 SPAIN MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 171 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 172 TURKEY INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 173 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 174 TURKEY POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 175 TURKEY MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 176 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 177 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 178 TURKEY ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 179 TURKEY PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 TURKEY MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 181 TURKEY PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 TURKEY TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 TURKEY BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 TURKEY CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 TURKEY NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 TURKEY INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 TURKEY OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 TURKEY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 189 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 190 SWITZERLAND INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 191 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 192 SWITZERLAND POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 193 SWITZERLAND MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 195 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 196 SWITZERLAND ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 197 SWITZERLAND PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 198 SWITZERLAND MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 199 SWITZERLAND PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 200 SWITZERLAND TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 201 SWITZERLAND BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 202 SWITZERLAND CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 203 SWITZERLAND NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 204 SWITZERLAND INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 205 SWITZERLAND OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 206 SWITZERLAND MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 207 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 208 BELGIUM INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 209 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 BELGIUM POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 BELGIUM MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 213 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 214 BELGIUM ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 215 BELGIUM PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 BELGIUM MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 217 BELGIUM PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 218 BELGIUM TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 219 BELGIUM BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 BELGIUM CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 BELGIUM NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 BELGIUM INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 BELGIUM OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 BELGIUM MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 225 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 226 NETHERLANDS INSTRUMENTS IN MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 227 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 NETHERLANDS POLYMERASE CHAIN REACTION (PCR)-BASED METHODS IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 NETHERLANDS MOLECULAR IMAGING IN MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 230 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 231 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY CANCER TYPE, 2019-2028 (USD MILLION)
TABLE 232 NETHERLANDS ONCOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 233 NETHERLANDS PHARMACOGENOMICS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 234 NETHERLANDS MICROBIOLOGY IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 235 NETHERLANDS PRENATAL TESTS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 236 NETHERLANDS TISSUE TYPING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 237 NETHERLANDS BLOOD SCREENING IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 238 NETHERLANDS CARDIOVASCULAR DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 239 NETHERLANDS NEUROLOGICAL DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 240 NETHERLANDS INFECTIOUS DISEASES IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 241 NETHERLANDS OTHERS IN MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 242 NETHERLANDS MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 243 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE MOLECULAR DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE MOLECULAR DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE MOLECULAR DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE MOLECULAR DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE MOLECULAR DIAGNOSTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE MOLECULAR DIAGNOSTICS MARKET AND GROWING WITH THE HIGHEST SHARE IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER IS EXPECTED TO DRIVE THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MOLECULAR DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE MOLECULAR DIAGNOSTICS MARKET
FIGURE 14 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2020
FIGURE 15 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020
FIGURE 16 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2020
FIGURE 17 EUROPE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2020
FIGURE 18 EUROPE MOLECULAR DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 19 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 20 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 21 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 22 EUROPE MOLECULAR DIAGNOSTICS MARKET: BY PRODUCT (2021 & 2028)
FIGURE 23 EUROPE MOLECULAR DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
